Quanterix’ ultra-sensitive digital biomarker detection solution, Simoa®, has the potential to transform the approach to healthcare by giving researchers much deeper insight into the role of biomarkers in the continuum of health to disease. Simoa is designed to enable earlier disease detection, better prognosis, and more precise treatment methods, and is being used by a rapidly growing network of academic researchers and pharmaceutical and biotech partners.
Simoa can quantify neurological biomarkers at ultra-low levels, providing the potential to radically change the way diseases are diagnosed. Paired with Quanterix’ comprehensive range of assays, including Tau, NFL, and amyloid beta, and now p-tau181, Simoa can detect these and many other biomarkers at much earlier stages to better understand the long-term effects and disease pathology. Most notably, thanks to our unparalleled sensitivity, biomarkers can be measured in relatively small samples of plasma or serum, obviating the need to obtain cerebrospinal fluid.